Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial. by Grunfeld, Eva et al.
UC Davis
UC Davis Previously Published Works
Title
Improving chronic disease prevention and screening in primary care: results of the 
BETTER pragmatic cluster randomized controlled trial.
Permalink
https://escholarship.org/uc/item/5xj8j10r
Journal
BMC family practice, 14(1)
ISSN
1471-2296
Authors
Grunfeld, Eva
Manca, Donna
Moineddin, Rahim
et al.
Publication Date
2013-11-20
DOI
10.1186/1471-2296-14-175
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Grunfeld et al. BMC Family Practice 2013, 14:175
http://www.biomedcentral.com/1471-2296/14/175RESEARCH ARTICLE Open AccessImproving chronic disease prevention and
screening in primary care: results of the BETTER
pragmatic cluster randomized controlled trial
Eva Grunfeld1,2*, Donna Manca3†, Rahim Moineddin1†, Kevin E Thorpe4,5†, Jeffrey S Hoch6,7,9,10†,
Denise Campbell-Scherer3†, Christopher Meaney1†, Jess Rogers8†, Jaclyn Beca6,7†, Paul Krueger1†,
Muhammad Mamdani4,9,10† for the BETTER Trial InvestigatorsBackground: Primary care provides most of the evidence-based chronic disease prevention and screening services
offered by the healthcare system. However, there remains a gap between recommended preventive services and
actual practice. This trial (the BETTER Trial) aimed to improve preventive care of heart disease, diabetes, colorectal,
breast and cervical cancers, and relevant lifestyle factors through a practice facilitation intervention set in
primary care.
Methods: Pragmatic two-way factorial cluster RCT with Primary Care Physicians’ practices as the unit of allocation
and individual patients as the unit of analysis. The setting was urban Primary Care Team practices in two Canadian
provinces. Eight Primary Care Team practices were randomly assigned to receive the practice-level intervention or
wait-list control; 4 physicians in each team (32 physicians) were randomly assigned to receive the patient-level
intervention or wait-list control. Patients randomly selected from physicians’ rosters were stratified into two groups:
1) general and 2) moderate mental illness. The interventions involved a multifaceted, evidence-based, tailored
practice-level intervention with a Practice Facilitator, and a patient-level intervention involving a one-hour visit with
a Prevention Practitioner where patients received a tailored ‘prevention prescription’. The primary outcome was a
composite Summary Quality Index of 28 evidence-based chronic disease prevention and screening actions with
pre-defined targets, expressed as the ratio of eligible actions at baseline that were met at follow-up.
A cost-effectiveness analysis was conducted.
Results: 789 of 1,260 (63%) eligible patients participated. On average, patients were eligible for 8.96 (SD 3.2) actions
at baseline. In the adjusted analysis, control patients met 23.1% (95% CI: 19.2% to 27.1%) of target actions,
compared to 28.5% (95% CI: 20.9% to 36.0%) receiving the practice-level intervention, 55.6% (95% CI: 49.0% to
62.1%) receiving the patient-level intervention, and 58.9% (95% CI: 54.7% to 63.1%) receiving both practice- and
patient-level interventions (patient-level intervention versus control, P < 0.001). The benefit of the patient-level
intervention was seen in both strata. The extra cost of the intervention was $26.43CAN (95% CI: $16 to $44) per
additional action met.
Conclusions: A Prevention Practitioner can improve the implementation of clinically important prevention and
screening for chronic diseases in a cost-effective manner.
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Most industrialized countries are facing an unprecedented
rise in chronic disease, with many patients suffering from
multiple chronic conditions [1,2]. Primary prevention and
screening for chronic diseases are considered the best hope
to curtail this rise [3,4]. Agencies such as the National
Institute for Health and Clinical Excellence [5], Canadian
Task Force on Preventive Health Care; [6] and the US Pre-
ventive Services Task Force [7] synthesize and grade their
recommended chronic disease prevention and screening
(CDPS) actions based on high level clinical trial evidence
that these actions will lead to improved clinical outcomes.
For example, it is estimated that 25% of all direct medical
costs are attributable to a small number of excess risk fac-
tors such as smoking, obesity, physical inactivity and poor
nutrition [8]. Even a 10% reduction in the prevalence of
physical inactivity, for example, could lead to substantial
reductions in direct health-care expenditures [2]. Similarly,
improving screening rates can reduce colorectal cancer
deaths by 15% to 33% [9] and cardiovascular risk assess-
ment with blood pressure readings has been shown to re-
duce population level cardiovascular morbidity [10]. The
challenge for healthcare systems worldwide is to improve
rates of CDPS that are recommended based on high level
evidence that they lead to improved outcomes [7].
Primary care, as the site of the patient’s medical home,
[11] is an effective and efficient setting to provide
evidence-based care [12]. Many of the evidence-based ac-
tions and strategies for CDPS are set in primary care and
supported by clinical practice guidelines [13]. However,
there remains a gap between recommended CDPS and ac-
tual practice, [14] due in part to the competing care de-
mands on Primary Care Physicians. For example, one
study found the time required to provide all recom-
mended preventive services to a typical family practice is
7.4 hours per working day, which would leave little time
for other patient care activities [14]. Furthermore, patients
with mental illness are a vulnerable subgroup with high
prevalence in primary care [15]. Due to the complexity of
dealing with multiple medical issues, these patients experi-
ence a large gap in preventive care, making this an import-
ant subgroup to target for improved CDPS [16-18].
Evidence on how best to implement effective care has
shown that tailored, active, and multifaceted interventions
using an amalgam of strategies are most effective [19-22].
Among the effective strategies is practice facilitation, a
process by which a trained individual – usually external to
the practice and not involved in direct patient care [23] -
supports primary care practices to improve the quality of
care [24,25]. However, a modification of practice facilita-
tion involving direct patient contact and applied to improv-
ing chronic disease prevention and screening concurrently
for several chronic diseases has not previously been tested.
We studied a multi-level [26] strategy using a modificationof practice facilitation to implement integrated prevention
and screening of chronic diseases (i.e., one that integrates
heart disease, diabetes, cancer and the lifestyle factors asso-
ciated with these diseases) based in primary care.
The objective of the trial “Building on Existing Tools to
Improve Chronic Disease Prevention and Screening in Pri-
mary Care (the BETTER trial) was to improve uptake of
clinically effective CDPS actions for primary prevention of
heart disease and diabetes, screening for colorectal, breast
and cervical cancers, and relevant lifestyle factors through
an implementation trial of a multifaceted multi-level tai-
lored intervention set in primary care and predicated on a
model of practice facilitation compared to standard care.
Methods
Primary care team practices
The setting was urban Primary Care Team practices in two
Canadian provinces identified by purposive sampling to
obtain a mix of academic teaching practices and commu-
nity non-teaching practices in different locations. Primary
Care Team practices are integrated primary care delivery
models, [27] that serve as their patients’ medical home
[11]. These are general practices that provide first contact
with the health care system including long-term person
and family focused care for all of their patients’ health
needs, including access to other resources such as specialty
services. All participating practices had been using an elec-
tronic medical record (EMR) system to manage their prac-
tice for at least two years.
Patients
Eligible patients were identified through the EMR and in-
cluded all active patients (seen within the previous three
years) age 40 to 65 years and rostered to one of the partici-
pating physicians. This age group was selected because of
the applicability of most CDPS actions to this age group
for both men and women. Patients were excluded if they
were not able to give informed consent or attend the prac-
tice for the intervention. Patients were stratified into two
mutually exclusive groups: Stratum 1: general medical pa-
tients and Stratum 2: patients with moderate mental illness
(defined as a diagnosis of depression, anxiety or psycho-
somatic disorder within the previous 12 months plus two
instances of diagnosis or one diagnosis and one prescrip-
tion). All participants gave written informed consent.
Design and intervention
We conducted a pragmatic two-way factorial cluster ran-
domized controlled trial (RCT) with physicians’ practices
as the unit of allocation and individual patients as the unit
of analysis involving a practice-level and patient-level fa-
cilitation intervention. The study was conducted in eight
Primary Care Team practices, with four physicians in each
team agreeing to participate for a total of 32 participating
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randomly assigned to the practice-level intervention or
wait-list control group. The four participating physicians
within each Primary Care Team practice were randomly
assigned to the patient-level intervention or wait-list con-
trol group (Figure 1). In this way participants were assigned
to one of four groups: 1) both the practice-level and
patient-level control; 2) both the practice-level and patient-
level intervention; 3) the practice-level control and patient-
level intervention; or 4) the practice-level intervention and
patient-level control. Randomization was at the level of the
physician (rather than the individual patient) to avoid con-
tamination. In total, eight physicians received no interven-
tion (wait-list control), eight physicians received only the
practice-level intervention, eight physicians received only
the patient-level intervention, and eight physicians re-
ceived both the practice - and patient -level intervention.
Using the EMR, the practice roster of each participating
physician was searched and a list of patients meeting the
eligibility criteria and a random number sequence was
generated for each stratum separately. Patients were in-
vited to participate according to the random number se-
quence until the target sample size for each physician was
reached or the patient list exhausted. A letter, signed by
the physician, was mailed with study documents to invite
patients to participate.
The intervention consisted of a practice-level interven-
tion with a Practice Facilitator and a patient-level interven-
tion with a Prevention Practitioner. Training for these
roles consisted of: 1) participation in the Clinical Working
Group (described below); a two-day training workshop
followed by a one-day training workshop before the inter-
vention started; and 3) during the intervention period thereOntario
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Patient 
Intervention
P
C
C C
C C C C CC C C
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Figure 1 Trial design schema.was the opportunity to participate in one-hour monthly
teleconferences that were facilitated by a member of the
Clinical Working Group.Practice-level intervention with a practice facilitator
The multifaceted practice-level intervention was predicated
on a model of outreach facilitation [24,25], provided by a
trained Practice Facilitator. Each Practice Facilitator sup-
ported two Primary Care Team practices (eight physicians).
The Practice Facilitator received training in practice facili-
tation and in the use of the EMR. An EMR audit tool was
developed to evaluate each physician’s use of the EMR.
Using the EMR audit, potential improvements in the use
of the EMR were identified. Each practice-level ‘prescrip-
tion’ fell into one of five categories: 1) discrete field to
check if the a field is available to enter data; 2) data discip-
line to check if a value is being entered in a consistent
location and standard way; 3) registry to determine if a
measure can be extracted into a report or patient list; 4)
usage to determine if the measure is being used consist-
ently; and 5) resources to assess the functionality of the
EMR to facilitate the use of a measure such as reminder
or alerts. The Practice Facilitator applied evidence-based
strategies including using the EMRs for reminder systems,
audit and feedback [28] applying quality improvement
techniques, [29] and a needs assessment of barriers and
supports to improve CDPS. The Practice Facilitator devel-
oped a practice-level ‘prevention prescription’ tailored to
the needs of the Primary Care Team practice (see BET-
TER Trial website for trial-specific tools) [30]. An example
could be a prescription to develop a discrete field and data
discipline to identify smokers in the practice.Random 
Allocation
Random 
Selection
atient Wait-list 
ontrol R RS
Alberta
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Each Primary Care Team practice designated an allied
health care professional (e.g., nurse practitioner, nurse or
dietician) from within the practice who was trained by
the BETTER Trial Clinical Working Group to undertake
the role of Prevention Practitioner. Following informed
consent, intervention patients were scheduled for a one-
hour visit with the Prevention Practitioner. Through
motivational interviewing and shared decision-making, a
personalized ‘prevention prescription’ was prepared by
the Prevention Practitioner during the visit. This pre-
scription was tailored to that patient’s chronic disease
risk as determined from their health record and trial-
specific “Health Survey” which the patient completed
before the visit, which also incorporated their family his-
tory (Additional file 1 - Appendix 1). The prevention
prescription focused on optimum use of existing cap-
acity, tools and community resources that were available
through: 1) the practice itself (e.g., fecal occult blood
testing kits, referral to the practice dietician or smoking
cessation program); 2) external referrals for tests, spe-
cialists, or resources (e.g., screens like mammography,
community weight loss programs); and 3) Internet pa-
tient resources. CDPS actions were included based on
evidence that they lead to clinically important benefits.
CDPS actions were identified through a comprehensive
review of the literature and approved by the Clinical
Working Group (Campbell-Scherer DL, Rogers J, Manca
D, et al. Evidence Translation Plan for the BETTER
Trial. Manuscript submitted to Can Med Assoc J). (See
BETTER Trial website for trial-specific tools [30].)
Recruitment and follow-up
Patient recruitment occurred August 2010 through
April 2011, and follow-up of all patients was completed
November 2011. Consenting patients completed the
baseline assessment and received the intervention at
baseline (T0) with outcome assessment at follow-up at
7 months (T1).
Outcome
CDPS actions that have been shown to lead to clinically im-
portant benefits for primary prevention of heart disease
and diabetes, screening for colorectal, breast, and cervical
cancers, and lifestyle factors relevant to chronic disease pre-
vention (alcohol consumption, smoking, diet, and physical
activity) were included. Included actions were determined
through an evidence review and appraisal by the Clinical
Working Group comprised of clinicians with expertise in
the relevant clinical areas supported by the Centre for
Effective Practice in Toronto, Canada. This yielded a total
of 28 actions for which targets were pre-defined (see
Additional file 1 - Appendix 2 for a description of the 28
actions, pre-defined targets, and supporting references).The primary outcome was a composite index, expressed
as the ratio (multiplied by 100) of the number of eligible
CDPS actions at baseline (denominator) that were subse-
quently met at follow-up (numerator), measured at the pa-
tient level. The composite index was modeled after the
Summary Quality Index (SQUID) introduced by Nietert
for assessing the quality of primary care interventions
[31]. As a function of baseline characteristics, certain indi-
viduals were eligible [E] for certain CDPS actions. At
follow-up, each patient was re-evaluated and the number
of eligible actions which they met [M] were enumerated.
For example, eligible actions would be smoking cessation
in an actively smoking patient or a mammogram in a
patient not up-to-date with her screening mammo-
grams. In this case, the actions would be designated
‘met’ if the patient had quit smoking and had a screen-
ing mammogram at follow-up. If the patient had not
quite smoking or the mammogram was not completed
at follow-up these actions were considered ‘not met’
(Additional file 1 - Appendix 2).
Measures and data sources
The primary data source was the patient’s EMR. The sec-
ondary data source was a trial specific patient-completed
Health Survey mailed to each patient at T0 and T1. The
eligible CDPS actions for each patient were determined
from the EMR for the two years prior to T0 and the base-
line Health Survey (Additional file 1 - Appendix 1). The
CDPS actions met by each patient were determined from
the EMR and the Health Survey at T1.
Sample size estimation and statistical analysis
Based on an estimated standard deviation of 20% and an
intra-class correlation coefficient of 0.237, we calculated
that 896 patients (28 per participating physician) were
needed for 80% power to detect an increase in SQUID
by 15% or higher with 5% Type I error [32,33].
The analysis was intention to treat. The analytic ap-
proach investigated the impact of the intervention (prac-
tice-level, patient-level, both practice- and patient-level vs
control). The trial design results in patient outcomes being
clustered within physician offices. Generalized Estimating
Equation (GEE) methods, using a compound symmetric
working correlation structure, were used to model this de-
pendence. Generalized score tests were used to assess the
significance of potential predictors in this regression frame-
work. Further, Wald tests were used to make comparisons
between interventions [34,35]. We used a two-way factorial
linear GEE model (i.e., containing a main effect for both
the Prevention Practitioner and Prevention Facilitator
intervention and an interaction effect between the Preven-
tion Practitioner and the Prevention Facilitator) to assess
the impact of each intervention on SQUID. If a non-
significant interaction effect was observed we considered a
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only a main effect for the Prevention Practitioner interven-
tion and the Prevention Facilitator intervention). The pri-
mary analysis involved estimating a two-way factorial
linear GEE model adjusting for potential confounders. The
statistical data analyses were completed using SAS v.9.3.
Economic evaluation
Cost-effectiveness analysis from the perspective of the
health care payer estimated the cost for improvement in
eligible actions met for each of the interventions. Costs in-
cluded practitioner training and time to administer the
intervention, and resources required to accomplish add-
itional actions. The times required to train for and admin-
ister the intervention were collected through detailed time
logs kept by the Prevention Practitioners and Prevention
Facilitators and included in the intervention costs. Time
that was specific to conducting the research was also re-
corded and excluded from the intervention costs (e.g.,
time spent obtaining patient consent). The resources used
were identified from standard costing sources in Ontario
and Alberta. (See Additional file 1 - Appendix 3 for list of
resources and costs for the economic evaluation.) All costs
were in Canadian dollars. The cost-effectiveness estimate
was computed as the ratio of the difference between the
total costs of each group to the difference in eligible actions
met by each group, or incremental cost-effectiveness ratio
(ICER). Incremental costs and effects between groups were
computed using GEE to account for clustering and ad-
justed for characteristics presented in Table 1. The results
were confirmed using net benefit regression [36].
Study oversight
Trial oversight, including data management and coord-
ination, was jointly provided by the BETTER team and
the Applied Health Research Centre of the Li Ka Shing
Knowledge Institute of St. Michael’s Hospital, Toronto,
Canada. The trial was approved by the Ontario Cancer
Research Ethics Board (REB), University of Alberta REB,
and all relevant REBs in each province and at each
Primary Care Team site.
Results
Patients
There were 789 patients enrolled in the trial among 1,260
patients approached for consent, representing an accept-
ance rate of 63%. Of these, 12 withdrew consent, leaving
777 for analysis. As shown in the CONSORT diagram
(Figure 2), the return rate at T0 was 98.2% and similar
across all four randomizations groups; the return rate at
T1 was 81.6% ranging from 75.5% to 86.9% across groups.
Baseline characteristics were balanced across groups
(Table 1). Baseline eligibility for each of the 28 CDPS ac-
tions is presented in Table 2. The mean number of CDPSactions for which patients were eligible at baseline was
8.96 (SD 3.20).
Primary outcome
As shown in Table 3, the number of eligible CDPS actions
for each patient was balanced across groups. Considering
all patients, the mean SQUID was significantly higher for
patients receiving the Prevention Practitioner intervention
compared to controls, and compared to those receiving the
Prevention Facilitator intervention. Considering unadjusted
means, control patients met 21.0% of target actions, com-
pared to 28.4% in the Prevention Facilitator only group,
53.6% in the Prevention Practitioner only group, and 58.4%
in the Prevention Facilitator/Prevention Practitioner group
(Wald test; PP versus control, P < 0.001) (Table 3).
The unadjusted two-way factorial linear GEE model
suggested that there was no significant interaction effect
(P = 0.654). The two-way main effects linear GEE model
showed that the effect of Prevention Practitioner inter-
vention was significant (P < 0.001) while the Prevention
Facilitator was not (P = 0.085). The estimated ICC was
0.381 in the overall sample.
After adjusting for potential confounders, in the two-
way factorial linear GEE analysis, patients in the control
group met 23.1% (95% CI: 19.2% to 27.1%) of actions,
compared to 28.5% (95% CI: 20.9% to 36.0%) in the Pre-
vention Facilitator only group, 55.6% (95% CI: 49.0% to
62.1%) in the Prevention Practitioner only group, and
58.9% (95% CI: 54.7% to 63.1%) in the PF/PP group. The
impact of the Prevention Practitioner intervention was
significant (P < 0.001) while the impact of the Prevention
Facilitator intervention remained not significant (P =
0.16) (Additional file 1 - Appendix 4). No other covari-
ates had a statistically significant impact.
In the stratum of the general health patients, the ad-
justed difference in SQUID between the Prevention Facili-
tator/Prevention Practitioner group and the control group
was 36.8%; whereas, in the mental health stratum the ad-
justed difference in SQUID between the Prevention Facili-
tator/Prevention Practitioner group and control group
was 36.0%. This difference was not statistically significant
(P = 0.68). None of the other differences-in-difference esti-
mates were statistically significant.
The effect of the Prevention Facilitator and Preven-
tion Practitioner interventions for each of the 28 com-
ponents of the SQUID are presented graphically in
Figure 3. These estimates are displayed for descriptive
purposes only since the trial was not powered to study
each CDPS action separately.
Economic evaluation
The Prevention Practitioner intervention cost an add-
itional $76.21 per patient compared to control. The ICER
was $26.43 per additional action met for the patient-level
Table 1 Baseline characteristics of patients by randomization group (N = 777)
Control PF only PP only PF/PP
(N = 183) (N = 150) (N = 209) (N = 235)
Characteristic
Age – yr ± SD 54.0 ± 6.4 52.4 ± 7.2 53.3 ± 6.7 52.9 ± 6.9
Female sex -% 69 78 66 77
Minority race or ethnic group -% 11 12 12 11
≥1 yr post-secondary education -% 85 81 88 88
Employment -% Full-time or part-time 70 75 83 74
Marital status -% Married/common-law 73 71 74 83
Total household income -%
≥ 100,000 CAD 47 47 50 56
≥ 60,000-99,999 CAD 26 28 31 28
Current smoker -% 10 10 15 7
Current alcohol consumption -%
< 4 times per month 67 65 63 63
≥ 2 times per week 10 10 17 15
Exercise status -%
Extremely active 20 16 15 21
≤ mildly active 80 84 85 79
Body-mass index¶ – mean ± SD 25.2 ± 5.7 25.3 ± 5.1 26.4 ± 5.8 25.0 ± 4.7
Obese -% 14 16 25 16
GAD-7
Score - mean ± SD 6.0 ± (5.7) 4.8 ± (4.7) 5.7 ± (5.6) 4.8 ± (4.8)
Range 0 to 21 0 to 21 0 to 21 0 to 21
PHQ-9
Score - mean ± SD 5.4 ± (5.6) 5.2 ± (5.0) 6.2 ± (6.1) 5.0 (± 5.2)
Range 0 to 27 0 to 24 0 to 27 0 to 23
MOS social support score
– Mean ± SD 74.3 ± (24.6) 73.0 ± (25.9) 75.0 ± (24.7) 79.2 ± (22.1)
Follow-up time – days ± SD 212.3 ± (40.8) 213.9 ± (42.6) 229.6 ± (50.0) 234.6 ± (54.5)
PF: Practice Facilitator (practice-level intervention); PP: Prevention Practitioner (patient-level intervention).
PF/PP: Combined practice-level and patient-level intervention.
CAD: Canadian dollars.
Body mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Obesity is defined as a BMI ≥30.
GAD-7: Generalized Anxiety Disorder. Score for the 7 items ranges from 0 to 21; scores of 5, 10 and 15 represent cut points for mild, moderate and severe anxiety,
respectively [37].
PHQ-9: Patient Health Questionnaire-9. Scores for the nine items ranges from 0 to 27. Scores of 5, 15, and 20 represent cut points for mild, moderate and severe
major depressive disorder, respectively [38].
MOS Social Support Questionnaire: Scores for the 22 items range from 0 to 100, higher scores indicate higher level of self-perceived support [39].
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The Prevention Facilitator intervention had both higher
costs and lower effectiveness relative to the combin-
ation of Prevention Practitioner and control groups,
suggesting it was not efficient (Figure 4). The Preven-
tion Facilitator/Prevention Practitioner intervention
cost an additional $29.53 over the PP alone, resulting in
an ICER of $93.10 per additional action accomplished
(95% CI not defined [36]).Discussion
This trial showed that a Prevention Practitioner, taken
from within the practice and trained to conduct dedi-
cated prevention visits at which each patient was given a
tailored prevention prescription and directed to relevant
practice or community resources, improved CDPS by
32.5% compared to control. The benefit of the Preven-
tion Practitioner intervention was seen in both general
health and mental health strata.
Figure 2 Enrollment, randomization, and follow-up of patients.
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showed an overall effect size of 0.56 favoring practice
facilitation. Applying Baskerville’s approach calculating
effect size to this study resulted in an effect size of 1.45 for
the patient-level intervention and an effect size of 0.36 for
the practice-level intervention. In the Baskerville meta-
analysis, tailoring and intensity of practice-level interven-
tions were two attributes that had a significant impact on
the size of the effect [24]. It may be that these attributes
were not optimally accomplished in the implementation
of the practice-level intervention of this trial. Another
possible explanation for why we did not find a benefit for
the practice-level intervention is that the seven-month
timeframe was too short to detect an effect for the inter-
vention that only indirectly affected patients. Conversely,
the patient-level intervention with the Prevention Practi-
tioner had a direct impact on patient outcomes.
Our aim was to develop an intervention that was
feasible and practical to implement in the primary
care setting, and pragmatic in its design to enhance
generalizability and relevance [40,41]. The PreventionPractitioner intervention was a one hour visit to conduct
evidence-based shared decision making around CDPS
with the patient. The product was a personalized pre-
scription where the patient was given relevant tools and
referral to relevant resources. This co-ordination visit
was designed to make it feasible to implement in the pri-
mary care setting. It is recognized that changing lifestyle
factors generally requires more intensive interventions
than provided in this trial. Nevertheless, assessment and
advice in primary care can effectively help patients mod-
ify their behaviour [42,43]. The trial was powered to de-
tect a difference in SQUID and, accordingly, the cost-
effectiveness analysis considered the extra cost of an im-
proved CDPS related to SQUID. Since multiple chronic
diseases are positively impacted by the intervention, the
added cost of the Prevention Practitioner intervention is
likely small in comparison to the long-term costs of
managing these chronic diseases. In addition, we did not
capture costs savings associated with avoiding unneces-
sary actions, which if included could make the interven-
tion more attractive. We feel this represents good value
Table 2 Baseline eligibility of patients for prevention and screening actions by randomization group N (%)
Control PF only PP only PF/PP
Prevention and screening actions (N=, eligible)
1. Fasting blood sugar screening 61 (33.3) 35 (23.3) 77 (36.8) 82 (34.9)
2. Fasting blood sugar monitoring 8 (4.4) 4 (2.7) 13 (6.2) 3 (1.3)
3. Blood pressure screening 107 (58.5) 82 (54.7) 117 (56.0) 136 (57.9)
4. Blood pressure monitoring 40 (21.9) 44 (29.3) 50 (23.9) 58 (24.7)
5. Hypertension treatment 23 (12.6) 23 (15.3) 20 (9.6) 26 (11.1)
6. Framingham calculated 108 (59.0) 68 (45.3) 114 (54.5) 132 (56.2)
7. Framingham improved 21 (11.5) 15 (10.0) 25 (12.0) 19 (8.1)
8. LDL improved 22 (12.0) 18 (12.0) 20 (9.6) 21 (8.9)
9. Cholesterol treatment 22 (12.0) 19 (12.7) 20 (9.6) 21 (8.9)
10.Breast cancer screening (women only; N = 561) 48 (38.1) 40 (34.2) 51 (37.0) 59 (32.8)
11. Colorectal cancer screening 61 (33.3) 41 (27.3) 68 (32.5) 56 (23.8)
12. Cervical cancer screening (women only; N = 561) 43 (34.1) 35 (29.9) 37 (26.8) 51 (28.3)
13. BMI screening 43 (23.5) 22 (14.7) 58 (27.8) 41 (17.4)
14. Waist circumference measured 173 (94.5) 141 (94.0) 177 (84.7) 223 (94.9)
15. Weight control 94 (51.4) 87 (58.0) 129 (61.7) 134 (57.0)
16. Weight control referral 94 (51.4) 87 (58.0) 130 (62.2) 135 (57.4)
17. Smoking screening 31 (16.9) 30 (20.0) 18 (8.6) 85 (36.2)
18. Smoking cessation 22 (12.0) 18 (12.0) 36 (17.2) 22 (9.4)
19. Smoking cessation referral 22 (12.0) 18 (12.0) 36 (17.2) 22 (9.4)
20. Alcohol screening 61 (33.3) 36 (24.0) 36 (17.2) 96 (40.9)
21. Alcohol control 28 (15.3) 32 (21.3) 42 (20.1) 49 (20.9)
22. Alcohol cessation referral 28 (15.3) 32 (21.3) 42 (20.1) 49 (20.9)
23. Physical activity screening 162 (88.5) 138 (92.0) 164 (78.5) 222 (94.5)
24. Physical activity≥ 90 minutes/week 91 (49.7) 65 (43.3) 109 (52.2) 125 (53.2)
25. Physical activity program referral 91 (49.7) 65 (43.3) 109 (52.2) 125 (53.2)
26. Nutrition screening 125 (68.3) 66 (44.0) 129 (61.7) 139 (59.1)
27. Healthy diet score improved 15 (8.2) 10 (6.7) 20 (9.6) 13 (5.5)
28. Nutrition counseling referral 15 (8.2) 10 (6.7) 20 (9.6) 13 (5.5)
PF: Practice Facilitator (practice-level intervention).
PP: Prevention Practitioner (patient-level intervention).
PF/PP: Combined practice-level and patient-level intervention.
Body mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Obesity is defined as a BMI ≥30.
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much they are willing to pay to increase CDPS actions.
The principal limitation of the study is that it involved
urban Primary Care Team practices that had adopted
EMRs and, therefore, may not be representative of other
settings (e.g., solo or rural practices). However, the findings
are relevant to most countries as the use of EMRs and shift
to team-based ‘medical homes’ as the locus of primary care,
are the direction that primary care is developing in many
countries [44]. The intervention was multifaceted, where an
amalgam of evidence-based strategies was applied. The de-
sign of the study does not allow for distinguishing the effect
of each individual strategy separately. The language and lit-
eracy requirements of informed consent and completion ofthe Health Survey would impact participating patients and,
therefore, could limit generalizability to patients without
those skills [45]. Although this trial was not designed or
powered to test the effect of the intervention on each action
separately, with respect to lifestyle factors the effect was not
detected for smoking cessation (−5.6%) and weight control
(−2%), while there was an improvement in physical activity
(12.6%) and healthy diet (7.2%) compared to controls. It is
possible that a larger effect might be achieved with greater
intensity or longer follow-up. Of the 28 actions in the
SQUID, 5 were considered ‘met’ if they were recorded in
the EMR (Additional file 1: Appendix 2, Items 6, 14, 17, 29,
23). We included these actions because the evidence review
highlighted the importance of recoding this information in
Table 3 Prevention and screening actions by randomization group and strata (Mean ± SD)
Control PF only PP only PF/PP P value*
All patients; N 183 150 209 235
Eligible actions 9.1 ± 3.4 8.5 ± 3.2 8.9 ± 3.2 9.2 ± 3.1 0.57
Actions met 1.9 ± 1.8 2.6 ± 2.3 4.7 ± 2.7 5.3 ± 2.6 <0.001
SQUID 21.0 ± 17.5 28.4 ± 23.6 53.6 ± 26.0 58.4 ± 23.8 <0.001
Adjusted SQUID 23.1 (19.2 – 27.1) 28.5 (20.9 – 36.0) 55.6 (49.0 – 62.1) 58.9 (54.7 – 63.1)
Stratum 1:
General health patients: N 119 107 129 158
Eligible actions 8.9 ± 3.3 8.4 ± 3.1 8.5 ± 3.0 9.0 ± 3.0 0.80
Actions met 1.9 ± 1.7 2.7 ± 2.3 4.8 ± 2.5 5.3 ± 2.5 <0.001
SQUID 21.5 ± 16.8 30.3 ± 24.1 57.7 ± 25.1 59.7 ± 23.4 <0.001
Adjusted SQUID 23.5 (19.3 – 27.7) 31.6 (22.9 – 40.4) 60.0 (52.8 – 67.2) 60.3 (55.6 , 65.1)
Stratum 2:
Mental health patients; N 64 43 80 77
Eligible actions 9.5 ± 3.5 8.8 ± 3.4 9.6 ± 3.3 9.6 ± 3.5 0.56
Actions met 1.9 ± 1.8 2.4 ± 2.2 4.5 ± 2.9 5.3 ± 2.9 <0.001
SQUID 20.1 ± 18.7 23.6 ± 21.7 47.1 ± 26.2 55.7 ± 24.8 <0.001
Adjusted SQUID 21.0 (13.3 – 28.8) 21.3 (11.9 – 30.6) 46.6 (39.4 – 53.7) 57.0 (52.3 – 61.7)
PF: Practice Facilitator (practice-level intervention).
PP: Prevention Practitioner (patient-level intervention).
PF/PP: Combined practice-level and patient-level intervention.
SQUID: Summary Quality Index defined is the ratio of the number of CDPS actions met according to pre-defined targets to the number of actions for which the
patient was eligible.
*P values are based on two-sided Generalized Score Tests for equality of means across 4 groups.
Figure 3 Improvement in prevention and screening actions for practice facilitator and prevention practitioner groups compared to
controls. Legend: FBS = Fasting Blood Sugar; BP = Blood Pressure; LDL = Low-density Lipoprotein; CRC = Colorectal Cancer; BMI: Body Mass Index.
Grunfeld et al. BMC Family Practice 2013, 14:175 Page 9 of 12
http://www.biomedcentral.com/1471-2296/14/175
Eligible Actions Met
$26.43 / additional action met
$93.10 /additional action met
Figure 4 Costs and effects for control and treatment groups. The ratio of the difference in costs between two groups to the difference in
eligible actions accomplished represents the incremental cost-effectiveness ratio (ICER) (dotted line). PP/PF: Combined practice-level and
patient-level intervention. NB: The PF intervention is within the “efficiency frontier” so it is not considered an efficient use of resources.
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actions were balanced across randomization groups
(Table 2) and would, therefore, have similar weighting
across all groups.
Conclusions
This trial provides strong support for the benefits of a
multifaceted facilitation intervention directed at clinic-
ally important CDPS actions tailored to the individual
patient. The intervention was also effective for patients
with moderate mental illness. The cost-effectiveness of
analysis suggests that the patient-level intervention with
a Prevention Practitioner visit is economically attractive,
particularly when considering the potential of preventing
chronic diseases [1,46]. Although measuring long-term
outcomes was beyond the scope of this trial, the in-
cluded CDPS actions were specifically selected because
the evidence base was already strong that they lead to
improved long-term outcomes.
The BETTER Trial developed a framework that bridged
the gap of chronic disease prevention and screening know-
ledge to practice through an intervention that integrated
evidence-based actions for patients 40 to 65 years of age,
which were adapted to the practice setting. The patient-
level intervention with a Prevention Practitioner is a modi-
fication of practice facilitation, This modification of the
role involves an allied health professional from within the
team practice, specially trained in evidence-based chronic
disease prevention and screening actions, skills, tools
and resources applied through direct patient contact at a
dedicated ‘prevention’ visit.The role of a Prevention Practitioner who, through train-
ing, develops skills and expertise in CDPS can be a resource
to a specific practice or shared among several practices.
The BETTER Trial team continues to update training re-
sources and tools [30], and are currently testing adaptations
of the Prevention Practitioner intervention in different set-
tings across Canada, including those with large rural and
remote populations.
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